Asco 2021 – Bristol’s Lag3 case for a replacement for Yervoy
The Relativity-047 study shows that relatlimab has a big safety advantage over Yervoy, with just a slight decrease in clinical benefit.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
AACR 2020 preview – no Tigit, but plenty of novel mechanisms
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
Sanofi does a spring clean
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
